HUE046120T2 - DNS-szekvenciákat kódoló poli (A) szekvenciák stabilizálása - Google Patents

DNS-szekvenciákat kódoló poli (A) szekvenciák stabilizálása

Info

Publication number
HUE046120T2
HUE046120T2 HUE15738014A HUE15738014A HUE046120T2 HU E046120 T2 HUE046120 T2 HU E046120T2 HU E15738014 A HUE15738014 A HU E15738014A HU E15738014 A HUE15738014 A HU E15738014A HU E046120 T2 HUE046120 T2 HU E046120T2
Authority
HU
Hungary
Prior art keywords
stabilization
poly
sequence encoding
dna sequences
encoding dna
Prior art date
Application number
HUE15738014A
Other languages
English (en)
Inventor
Florian Eberle
Ugur Sahin
Andreas Kuhn
Britta Vallazza
Mustafa Diken
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of HUE046120T2 publication Critical patent/HUE046120T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HUE15738014A 2014-07-11 2015-07-06 DNS-szekvenciákat kódoló poli (A) szekvenciák stabilizálása HUE046120T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/064924 WO2016005004A1 (en) 2014-07-11 2014-07-11 Stabilization of poly(a) sequence encoding dna sequences

Publications (1)

Publication Number Publication Date
HUE046120T2 true HUE046120T2 (hu) 2020-02-28

Family

ID=51220548

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15738014A HUE046120T2 (hu) 2014-07-11 2015-07-06 DNS-szekvenciákat kódoló poli (A) szekvenciák stabilizálása

Country Status (14)

Country Link
US (2) US10717982B2 (hu)
EP (2) EP3167059B1 (hu)
JP (2) JP6759196B2 (hu)
AU (2) AU2015286820B2 (hu)
CA (1) CA2954706C (hu)
DE (2) DE202015010019U1 (hu)
DK (1) DK3167059T3 (hu)
ES (1) ES2735728T3 (hu)
HU (1) HUE046120T2 (hu)
PL (1) PL3167059T3 (hu)
PT (1) PT3167059T (hu)
SI (1) SI3167059T1 (hu)
TR (1) TR201910424T4 (hu)
WO (2) WO2016005004A1 (hu)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906527B (zh) 2011-06-08 2020-07-10 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
ES2670529T3 (es) 2013-03-15 2018-05-30 Translate Bio, Inc. Mejora sinergística de la entrega de ácidos nucleicos a través de formulaciones mezcladas
CA2963840A1 (en) * 2014-10-09 2016-04-14 Seattle Children's Hospital (dba Seattle Children's Research Institute) Long poly(a) plasmids and methods for introduction of long poly(a) sequences into the plasmid
WO2016091391A1 (en) 2014-12-12 2016-06-16 Curevac Ag Artificial nucleic acid molecules for improved protein expression
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
KR102369898B1 (ko) 2016-04-08 2022-03-03 트랜슬레이트 바이오 인코포레이티드 다량체 코딩 핵산 및 그 용도
JP2019522047A (ja) 2016-06-13 2019-08-08 トランスレイト バイオ， インコーポレイテッド オルニチントランスカルバミラーゼ欠損症治療のためのメッセンジャーｒｎａ療法
MA47680A (fr) 2017-02-28 2020-01-08 Sanofi Sa Arn thérapeutique
WO2019036513A1 (en) * 2017-08-15 2019-02-21 Intellia Therapeutics, Inc. STABILIZED NUCLEIC ACIDS ENCODING MESSENGER RIBONUCLEIC ACID (MRNA)
JP7424968B2 (ja) 2017-09-13 2024-01-30 バイオエヌテック エスエー 細胞におけるｒｎａ発現を増強する方法
WO2019053056A1 (en) 2017-09-13 2019-03-21 Biontech Cell & Gene Therapies Gmbh RNA REPLICON FOR EXPRESSING A T CELL RECEPTOR OR ARTIFICIAL LYMPHOCYTIC T CELL RECEPTOR
EP3681993A1 (en) 2017-09-13 2020-07-22 BioNTech RNA Pharmaceuticals GmbH Rna replicon for reprogramming somatic cells
AU2018392716A1 (en) 2017-12-20 2020-06-18 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
TW202026423A (zh) 2018-08-24 2020-07-16 法商賽諾菲公司 用於實體瘤癌症的治療性ｒｎａ
JP2022504663A (ja) 2018-10-11 2022-01-13 エスリス ゲーエムベーハー セグメント化されたポリ（Ａ）尾部を有するｍＲＮＡをコードする配列を含むプラスミド
WO2020154189A1 (en) 2019-01-21 2020-07-30 Sanofi Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers
EP3914354A1 (en) 2019-01-21 2021-12-01 Sanofi Therapeutic rna for advanced stage solid tumor cancers
MX2021010862A (es) 2019-03-12 2021-10-22 BioNTech SE Arn terapeutico para el cancer de prostata.
WO2020187848A1 (en) 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
WO2020200481A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)
BR112021022106A2 (pt) 2019-05-20 2021-12-28 BioNTech SE Rna terapêutico para câncer de ovário
TW202115105A (zh) 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
WO2021008708A1 (en) 2019-07-18 2021-01-21 Biontech Rna Pharmaceuticals Gmbh Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles
WO2021058091A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
WO2021129945A1 (en) 2019-12-27 2021-07-01 Biontech Cell & Gene Therapies Gmbh In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
EP4103228A1 (en) 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
WO2021175405A1 (en) 2020-03-02 2021-09-10 Biontech Rna Pharmaceuticals Gmbh Composite rna particles
JP2023518935A (ja) 2020-03-16 2023-05-09 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー 抗原特異的ｔ細胞受容体およびｔ細胞エピトープ
KR102462990B1 (ko) * 2020-03-17 2022-11-07 에이비온 주식회사 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물
WO2021198157A1 (en) 2020-03-30 2021-10-07 BioNTech SE Rna compositions targeting claudin-18.2
WO2021197589A1 (en) 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
CN111394378A (zh) * 2020-04-03 2020-07-10 深圳市新合生物医疗科技有限公司 一种体外表达mRNA的质粒载体及其构建方法和应用
KR20230015351A (ko) 2020-04-22 2023-01-31 화이자 인코포레이티드 코로나바이러스 백신
MX2022013254A (es) 2020-04-22 2023-01-24 BioNTech SE Vacuna contra el coronavirus.
AU2021286169A1 (en) 2020-06-04 2023-01-19 BioNTech SE RNA replicon for versatile and efficient gene expression
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
AU2021322046A1 (en) 2020-08-06 2023-02-02 BioNTech SE Binding agents for coronavirus S protein
TW202227478A (zh) 2020-09-15 2022-07-16 德商拜恩迪克公司 對細胞靶向遞送的藥劑及方法
US20230399403A1 (en) 2020-11-11 2023-12-14 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
US20240041785A1 (en) 2020-11-16 2024-02-08 BioNTech SE Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
TW202237148A (zh) 2020-11-16 2022-10-01 德商拜恩迪克公司 包含rna之lnp組合物以及製備、儲存及使用彼之方法
WO2022218503A1 (en) 2021-04-12 2022-10-20 BioNTech SE Lnp compositions comprising rna and methods for preparing, storing and using the same
US20240033344A1 (en) 2020-11-16 2024-02-01 BioNTech SE Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same
CA3201552A1 (en) 2020-12-09 2022-06-16 Thomas ZIEGENHALS Rna manufacturing
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
CA3215103A1 (en) 2021-04-12 2022-10-20 Steffen Panzner Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
CN117750974A (zh) 2021-04-20 2024-03-22 生物技术欧洲股份公司 病毒疫苗
KR20240006575A (ko) 2021-04-26 2024-01-15 앵스띠뛰 파스퇴르 SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도
AU2022270658A1 (en) 2021-05-04 2023-11-16 BioNTech SE Technologies for early detection of variants of interest
CN117715655A (zh) 2021-06-08 2024-03-15 生物技术细胞和基因治疗公司 用于活化和靶向免疫效应细胞的物质和方法
CA3226700A1 (en) 2021-07-15 2023-01-19 BioNTech SE Agents encoding cldn6 and cds binding elements for treating cldn6-positive cancers
CA3223943A1 (en) 2021-07-29 2023-02-02 Ugur Sahin Compositions and methods for treatment of melanoma
KR20230026965A (ko) * 2021-08-17 2023-02-27 에스케이바이오사이언스(주) 폴리 a 테일을 안정적으로 유지하는 방법
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
WO2023030635A1 (en) 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023036960A1 (en) 2021-09-10 2023-03-16 BioNTech SE Lipid-based rna formulations suitable for therapy
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
TW202333803A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性ｒｎａ（一）
WO2023061550A1 (en) 2021-10-11 2023-04-20 BioNTech SE Therapeutic rna for lung cancer
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
AU2022372325A1 (en) 2021-10-18 2024-05-02 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
AU2022369342A1 (en) 2021-10-18 2024-03-14 BioNTech SE Modified replicable rna and related compositions and their use
AU2021470029A1 (en) 2021-10-21 2024-05-02 BioNTech SE Coronavirus vaccine
EP4285933A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4286394A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4286004A1 (en) 2022-05-30 2023-12-06 BioNTech SE Disulfide oligosaccharide compounds and complexes
WO2023067125A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
EP4286003A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4169579A1 (en) 2021-10-22 2023-04-26 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4169580A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
WO2023067126A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide compounds and complexes
WO2023067121A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide compounds and complexes
WO2023067124A1 (en) 2021-10-22 2023-04-27 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4186528A1 (en) 2021-11-30 2023-05-31 BioNTech SE Oligosaccharide complexes and uses
EP4285932A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
AU2022374004A1 (en) 2021-10-22 2024-05-02 BioNTech SE Compositions for administration of different doses of rna
EP4169578A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4169534A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide complexes and uses
WO2023067123A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
WO2023073190A1 (en) 2021-10-28 2023-05-04 BioNTech SE Rna constructs and uses thereof
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
GB2615177A (en) 2021-11-29 2023-08-02 BioNTech SE Coronavirus vaccine
WO2023105005A1 (en) 2021-12-09 2023-06-15 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2024046572A1 (en) 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
WO2023147090A1 (en) 2022-01-27 2023-08-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2023147092A2 (en) 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
WO2023148277A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
WO2023148276A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery to cells
WO2023165681A1 (en) 2022-03-01 2023-09-07 BioNTech SE Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2023193892A1 (en) 2022-04-05 2023-10-12 BioNTech SE Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2023217987A1 (en) 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023218431A1 (en) 2022-05-13 2023-11-16 BioNTech SE Rna compositions targeting hiv
WO2023230295A1 (en) 2022-05-25 2023-11-30 BioNTech SE Rna compositions for delivery of monkeypox antigens and related methods
WO2023232747A1 (en) 2022-05-30 2023-12-07 BioNTech SE Complexes for delivery of nucleic acids
WO2023234661A1 (ko) * 2022-05-31 2023-12-07 경상국립대학교산학협력단 신규한 변형 폴리아데닌 서열 및 이의 용도
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
WO2024028325A1 (en) 2022-08-01 2024-02-08 BioNTech SE Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
WO2024028445A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
CN117701602A (zh) * 2022-08-26 2024-03-15 深圳瑞吉生物科技有限公司 在宿主细胞中稳定存在的多段化PolyA多核苷酸及其应用
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
WO2024064931A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024064934A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024068674A1 (en) 2022-09-26 2024-04-04 BioNTech SE Nucleic acid complexes and uses thereof
WO2024075022A2 (en) 2022-10-04 2024-04-11 BioNTech SE Rna constructs and uses thereof
WO2024074634A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024084462A1 (en) 2022-10-21 2024-04-25 BioNTech SE Nucleic acid complexes and uses thereof
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866422A (en) * 1997-10-29 1999-02-02 New England Biolabs, Inc. Method for cloning and producing the Tsp45I restriction endonuclease in E. coli
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
AU2011253592B2 (en) * 2005-09-28 2013-11-14 Biontech Ag Modification of RNA, producing an increased transcript stability and translation efficiency
US9249425B2 (en) * 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus

Also Published As

Publication number Publication date
US10717982B2 (en) 2020-07-21
PT3167059T (pt) 2019-07-29
US20170166905A1 (en) 2017-06-15
JP2020188758A (ja) 2020-11-26
DE202015010019U1 (de) 2023-06-02
CA2954706C (en) 2023-01-24
DE202015010020U1 (de) 2023-06-05
US20200392518A1 (en) 2020-12-17
AU2015286820B2 (en) 2021-09-09
ES2735728T3 (es) 2019-12-20
JP2017522050A (ja) 2017-08-10
JP7144481B2 (ja) 2022-09-29
EP3167059A1 (en) 2017-05-17
WO2016005324A1 (en) 2016-01-14
SI3167059T1 (sl) 2019-10-30
AU2021277776A1 (en) 2021-12-23
PL3167059T3 (pl) 2019-12-31
JP6759196B2 (ja) 2020-09-23
EP3167059B1 (en) 2019-06-26
EP3594337A1 (en) 2020-01-15
AU2015286820A1 (en) 2017-02-23
AU2015286820A8 (en) 2017-03-30
WO2016005004A1 (en) 2016-01-14
TR201910424T4 (tr) 2019-08-21
DK3167059T3 (da) 2019-08-05
CA2954706A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
PT3167059T (pt) Estabilização de sequências de adn codificando sequências de poli(a)
IL287206A (en) Improved vectors containing polyethyleneimine-polyethyleneglycol
HK1223049A1 (zh) 自定向注射器接口
IL250836B (en) Nucleotide analogs
SG11201610182SA (en) Molecular inks
GB2531126B (en) Production of poly(carborane-co-siloxane) polymers
GB201411503D0 (en) Galois field coding techniques
GB201417535D0 (en) Adapting encoding properties
IL251255A0 (en) Electric combustion reactor
SG11201607226UA (en) Codon-optimized nucleotide sequence encoding mg53, its recombinants and use thereof
TWM488998U (en) Syringe
LT3237612T (lt) Sekos variantai
SG11201704819WA (en) Syringe
GB201510966D0 (en) Syringes
GB2538110B (en) Systematic coding technique
GB201515996D0 (en) Synthetic nucleotide sequences
GB201515447D0 (en) Syringes
GB201509674D0 (en) Stabilisation of peg based polyurethane polymers
GB201409964D0 (en) Stabilsation of peg based polyurethane polymers
GB201412854D0 (en) Rhymeshow code
GB201408448D0 (en) Reaction chamber
GB201405405D0 (en) Digital identification code